|Print Page Close Window|
ALAMEDA, Calif., September 2, 2015 – ESI BIO (esibio.com), the stem cell products division of BioTime, Inc., announced today the release of its most recent technology platform designed to give researchers new standardized in vitro assays with greater physiological relevance and accuracy. The VascuNet™ Pericyte Co-Culture Assay provides a stable, clinically relevant angiogenesis model not currently obtainable with other vascular network systems.
This breakthrough technology in angiogenesis assays was developed in collaboration with ReCyte Therapeutics, Inc., another BioTime subsidiary, toward the goal of providing clinically relevant research platforms to the greater pharmaceutical drug screening and research community.
VascuNet™ Pericyte Co-Culture Assay
ESI BIO’s VascuNet™ Pericyte Co-Culture Assay is a novel angiogenesis model that, with the inclusion of both endothelial cells and pericytes, provides a more clinically relevant research platform. Cellular networks in this co-culture system can easily be maintained for extended periods of time in vitro, allowing for a more complete and accurate model to study the effects of drugs and therapeutic compounds on vascular network formation.
Angiogenesis (growth of new blood vessels) is a central process in development, reproduction, and wound healing. The normal state of angiogenesis is dysregulated in many serious diseases, where the formation of new blood vessels is either promoted excessively or inhibited by a variety of potential factors.
Proper angiogenesis requires tightly regulated interactions between endothelial cells and pericytes, branched cells embedded within the basement membrane of capillaries that reinforce vascular structure and aide in regulating blood flow. In fact, it’s believed that in many cases, the malfunction of pericytes is central to disease progression, including tumorigenesis, neurodegenerative disorders, and diabetic retinopathy.
The standardized PC-M cells included in the VascuNet™ kit are pericytes that were derived from a proprietary differentiation method using ESI BIO’s ESI-017 Human Embryonic Stem Cell Line. These cells have been shown to closely resemble the phenotype and functionality of human pericytes in vivo.
The proper interaction and balance between the endothelial cells and pericytes in an in vitro system is crucial to developing a sound research model of disease and to our understanding of vascular disorders. The defined protocol for the VascuNet™ Pericyte Co-Culture Assay allows for standardized testing of factors indicated in modulating or inhibiting angiogenesis on highly characterized cells with precise timing of environmental factors.
About ESI BIO
BioTime’s subsidiaries include the publicly traded Asterias Biotherapeutics, Inc., developing pluripotent stem cell-based therapies in neurology and oncology, including AST-OPC1 and AST-VAC2; Cell Cure Neurosciences Ltd., developing stem cell-based therapies for retinal and neurological disorders, including OpRegen®; OncoCyte Corporation, developing cancer diagnostics; LifeMap Sciences, Inc., developing and marketing an integrated online database resource for biomedical and stem cell research; LifeMap Solutions, Inc., a subsidiary of LifeMap Sciences, developing mobile health (mHealth) products; ES Cell International Pte Ltd, which has developed cGMP-compliant human embryonic stem cell lines that are being marketed by BioTime for research purposes under the ESI BIO branding program; OrthoCyte Corporation, developing therapies to treat orthopedic disorders, diseases, and injuries; and ReCyte Therapeutics, Inc., developing therapies to treat a variety of cardiovascular and related ischemic disorders.
ESI BIO - A Division of BioTime, Inc.
© Copyright BioTime, Inc.